Teladoc Health (NYSE:TDOC - Get Free Report) had its price target hoisted by investment analysts at Evercore ISI from $8.00 to $9.00 in a research note issued to investors on Wednesday,Benzinga reports. The brokerage presently has an "in-line" rating on the health services provider's stock. Evercore ISI's target price suggests a potential upside of 5.46% from the company's previous close.
A number of other brokerages have also recently weighed in on TDOC. Weiss Ratings restated a "sell (d-)" rating on shares of Teladoc Health in a report on Saturday, September 27th. Mizuho assumed coverage on shares of Teladoc Health in a report on Friday, July 25th. They issued a "neutral" rating and a $10.00 price objective for the company. Six analysts have rated the stock with a Buy rating, eleven have assigned a Hold rating and one has issued a Sell rating to the stock. According to data from MarketBeat.com, the company currently has an average rating of "Hold" and an average target price of $9.86.
Get Our Latest Report on Teladoc Health
Teladoc Health Stock Performance
NYSE:TDOC opened at $8.53 on Wednesday. The company has a current ratio of 2.67, a quick ratio of 2.58 and a debt-to-equity ratio of 0.70. The company's 50-day moving average price is $7.68 and its 200-day moving average price is $7.60. Teladoc Health has a twelve month low of $6.35 and a twelve month high of $15.21. The company has a market cap of $1.51 billion, a P/E ratio of -7.11 and a beta of 1.90.
Teladoc Health (NYSE:TDOC - Get Free Report) last issued its earnings results on Tuesday, July 29th. The health services provider reported ($0.19) EPS for the quarter, topping analysts' consensus estimates of ($0.27) by $0.08. Teladoc Health had a negative net margin of 8.16% and a negative return on equity of 10.13%. The company had revenue of $631.90 million for the quarter, compared to the consensus estimate of $621.91 million. During the same period in the previous year, the firm earned ($0.38) earnings per share. Teladoc Health's quarterly revenue was down 1.6% compared to the same quarter last year. Teladoc Health has set its Q3 2025 guidance at -0.350--0.200 EPS. FY 2025 guidance at -1.350--1.000 EPS. On average, sell-side analysts forecast that Teladoc Health will post -1.16 earnings per share for the current fiscal year.
Institutional Inflows and Outflows
Large investors have recently modified their holdings of the stock. Golden State Wealth Management LLC boosted its holdings in shares of Teladoc Health by 102.6% in the 1st quarter. Golden State Wealth Management LLC now owns 3,337 shares of the health services provider's stock valued at $27,000 after buying an additional 1,690 shares in the last quarter. National Bank of Canada FI raised its position in Teladoc Health by 79.4% during the 1st quarter. National Bank of Canada FI now owns 3,571 shares of the health services provider's stock worth $28,000 after buying an additional 1,581 shares during the last quarter. SVB Wealth LLC purchased a new position in Teladoc Health during the 1st quarter worth $37,000. BI Asset Management Fondsmaeglerselskab A S purchased a new position in Teladoc Health during the 1st quarter worth $50,000. Finally, Caitong International Asset Management Co. Ltd grew its stake in Teladoc Health by 8,192.0% in the 2nd quarter. Caitong International Asset Management Co. Ltd now owns 8,292 shares of the health services provider's stock valued at $72,000 after acquiring an additional 8,192 shares during the last quarter. Institutional investors and hedge funds own 76.82% of the company's stock.
About Teladoc Health
(
Get Free Report)
Teladoc Health, Inc provides virtual healthcare services worldwide. The company operates through Teladoc Health Integrated Care and BetterHelp segments. The Integrated Care segment offers virtual medical services, including general medical, expert medical, specialty medical, chronic condition management, and mental health, as well as enabling technologies and enterprise telehealth solutions for hospitals and health systems.
Recommended Stories

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.
Before you consider Teladoc Health, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Teladoc Health wasn't on the list.
While Teladoc Health currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Market downturns give many investors pause, and for good reason. Wondering how to offset this risk? Enter your email address to learn more about using beta to protect your portfolio.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.